M
Maureen Lowery
Researcher at University of California, San Francisco
Publications - 3
Citations - 2245
Maureen Lowery is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Hormone therapy & Medroxyprogesterone acetate. The author has an hindex of 3, co-authored 3 publications receiving 2195 citations.
Papers
More filters
Journal ArticleDOI
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Stephen B. Hulley,Curt D. Furberg,Elizabeth Barrett-Connor,Jane A. Cauley,Deborah Grady,William L. Haskell,Robert H. Knopp,Maureen Lowery,Suzanne Satterfield,Helmut G. Schrott,Eric Vittinghoff,Donald B. Hunninghake +11 more
TL;DR: Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up, and hormone therapy did not reduce risk of cardiovascular events in women with CHD.
Journal ArticleDOI
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II)
Stephen B. Hulley,Curt D. Furberg,Elizabeth Barrett-Connor,Jane A. Cauley,Deborah Grady,William L. Haskell,Robert H. Knopp,Maureen Lowery,Suzanne Satterfield,Helmut G. Schrott,Eric Vittinghoff,Donald B. Hunninghake +11 more
TL;DR: HRT should be used only for symptomatic relief in the early postmenopausal years or any other indication supported by evidence from randomized trials, providing that the potential benefit outweighs any harmful effects.
Journal ArticleDOI
Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy
Robert P. Byington,Curt D. Furberg,David M. Herrington,J.Alan Herd,Donald B. Hunninghake,Maureen Lowery,Ward A. Riley,Timothy E. Craven,Lily A. Chaput,Christine C. Ireland,William B. Applegate +10 more
TL;DR: The Heart and Estrogen/Progestin Replacement Study (HERS) found no overall effect of estrogen plus progestin (compared with placebo) on coronary event rates in 2763 postmenopausal women with established coronary disease, supporting the American Heart Association recommendation that women withestablished coronary disease should not initiate hormone therapy with an expectation of atherosclerotic benefit.